Matthew L. Sherman

2021 - Deciphera Pharmaceuticals

In 2021, Matthew L. Sherman earned a total compensation of $3.5M as EVP, Chief Medical Officer at Deciphera Pharmaceuticals, a 166% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$189,067
Option Awards$2,103,820
Salary$525,185
Stock Awards$632,922
Other$11,600
Total$3,462,594

Sherman received $2.1M in option awards, accounting for 61% of the total pay in 2021.

Sherman also received $189.1K in non-equity incentive plan, $525.2K in salary, $632.9K in stock awards and $11.6K in other compensation.

Rankings

In 2021, Matthew L. Sherman's compensation ranked 3,869th out of 12,405 executives tracked by ExecPay. In other words, Sherman earned more than 68.8% of executives.

ClassificationRankingPercentile
All
3,869
out of 12,405
69th
Division
Manufacturing
1,583
out of 5,494
71st
Major group
Chemicals And Allied Products
647
out of 2,369
73rd
Industry group
Drugs
575
out of 2,090
73rd
Industry
Pharmaceutical Preparations
402
out of 1,537
74th

Pay ratio

Matthew L. Sherman's Pay$3,462,594
Median Employee's Pay$290,520
Pay Ratio

12

to 1

In 2021, the annual total compensation of Matthew L. Sherman was $3,462,594.

The annual total compensation of the median employee at Deciphera Pharmaceuticals was $290,520.

The ratio of Matthew L. Sherman's pay to the pay of median employee was therefore 12 to one.

Source: SEC filing on April 26, 2022.

Sherman's colleagues

We found four more compensation records of executives who worked with Matthew L. Sherman at Deciphera Pharmaceuticals in 2021.

2021

Steven Hoerter

Deciphera Pharmaceuticals

Chief Executive Officer

2021

Daniel Flynn

Deciphera Pharmaceuticals

Chief Scientific Officer

2021

Thomas Kelly

Deciphera Pharmaceuticals

Chief Financial Officer

2021

Daniel Martin

Deciphera Pharmaceuticals

Chief Commercial Officer

News

In-depth

You may also like